Immunotherapy: should we worry about immunosenescence?

Area of Science:

• Geriatric Oncology
• Immunotherapy
• Cancer Research

Background:

• The global population is aging, leading to increased cancer incidence in older adults.
• Immune checkpoint inhibitors (ICIs) are widely used but their efficacy and safety in elderly patients are influenced by immunosenescence, the age-related decline in immune function.
• Challenges remain regarding resistance to immunotherapy and severe immune-related adverse events (irAEs) in this demographic.

Purpose of the Study:

• To explore the complex relationship between immunosenescence and the efficacy and safety of ICI therapy in older and frail cancer patients.
• To highlight the need for research correlating immunosenescence markers with treatment outcomes and irAEs.
• To emphasize the importance of understanding these factors for advancing geriatric oncology.

Main Methods:

• This commentary reviews existing literature and discusses the interrelationship between immunosenescence, frailty, and ICI therapy.
• It focuses on the potential impact of peripheral blood immunosenescence markers on the tumor microenvironment (TME) and treatment response.
• The review also considers the occurrence and management of irAEs in older patients.

Main Results:

• Limited research currently exists on the direct correlation between immunosenescence markers and ICI treatment outcomes or irAEs in older adults.
• Immunosenescence is hypothesized to influence both the effectiveness of immunotherapy and the risk of adverse events.
• Understanding these associations is critical for predicting patient response and managing side effects.

Conclusions:

• Identifying reliable biomarkers of immunosenescence is essential for stratifying older patients for ICI therapy.
• Personalized treatment approaches are needed to improve outcomes and minimize risks in geriatric oncology.
• Further research is crucial to elucidate the role of immunosenescence in cancer immunotherapy for elderly and frail populations.